1. Search Result
Search Result
Results for "

GPX4

" in MedChemExpress (MCE) Product Catalog:

68

Inhibitors & Agonists

2

Biochemical Assay Reagents

5

Natural
Products

2

Recombinant Proteins

1

Isotope-Labeled Compounds

2

Antibodies

3

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-161929

    Glutathione Peroxidase Ferroptosis Cardiovascular Disease
    GPX4 activator 2 (Compound C3) is an activator of GPX4. GPX4 activator 2 exhibits cardioprotective effects and can inhibit cellular ferroptosis (EC50 = 7.8 μM)。GPX4 activator 2 can be used in the research of myocardial injury .
    GPX4 activator 2
  • HY-141809
    GPX4-IN-3
    2 Publications Verification

    Glutathione Peroxidase Ferroptosis Cancer
    GPX4-IN-3 (26a) is a potent glutathione peroxidase 4 (GPX4) inhibitor as a selective ferroptosis inducer. GPX4-IN-3 (26a) exhibits 71.7% inhibition for GPX4 with 1 μM .
    GPX4-IN-3
  • HY-138556

    Glutathione Peroxidase Cancer
    GPX4-IN-2 is a potent GPX4 inhibitor. GPX4 shows antiproliferative activity. GPX4-IN-2 has the potential for the research of cancer .
    GPX4-IN-2
  • HY-161928

    Glutathione Peroxidase Ferroptosis Cancer
    GPX4 activator 1 (Compound A9) is a allosteric activator of GPX4 (Kd = 5.86 μM, EC50 = 19.19 μM). GPX4 activator 1 can selectively act on ferroptosis and prevent the accumulation of intracellular lipid peroxides caused by ferroptosis inducers .
    GPX4 activator 1
  • HY-RS05767

    Small Interfering RNA (siRNA) Others

    GPX4 Human Pre-designed siRNA Set A contains three designed siRNAs for GPX4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    GPX4 Human Pre-designed siRNA Set A
    GPX4 Human Pre-designed siRNA Set A
  • HY-163272

    Glutathione Peroxidase CDK Cancer
    GPX4/CDK-IN-1 (Compound B9) is a dual inhibitor of GPX4 and CDK, with IC50 values of 542.5 nM, 191.2 nM and 68.1 nM for GPX4, CDK4 and CDK6, reapectively. GPX4/CDK-IN-1 shows strong cancer cell growth inhibition in vivo .
    GPX4/CDK-IN-1
  • HY-163995

    Ferroptosis Glutathione Peroxidase Cancer
    GPX4-IN-13 (compound 16) is a GPX4 inhibitor with anticancer activity. GPX4-IN-13 reduces thyroid cell proliferation and induces ferroptosis by inhibiting the expression level of GPX4. GPX4-IN-13 inhibits the growth of three thyroid cancer cell lines: N-thy-ori-3-1 (IC50=8.39 μM), MDA-T32 (IC50=10.28 μM) and MDA-T41 (IC50=8.18 μM) .
    GPX4-IN-13
  • HY-156286

    Ferroptosis Cancer
    GPX4-IN-7 (Compound 31), indirubin derivative, is a ferroptosis inducer for colon cancer. GPX4-IN-7 has strong antitumor activity against HCT-116 cells with an IC50 value of 0.49 μM. GPX4-IN-7 can promote the degradation of GPX4, causing the accumulation of lipid ROS to induce ferroptosis .
    GPX4-IN-7
  • HY-168879

    Glutathione Peroxidase Cancer
    GPX4-IN-16 ((R)-9i) is a potent GPX4 inhibitor with an KD value of 20.4 nM. GPX4-IN-16 shows cytotoxicity. GPX4-IN-16 shows anticancer activity .
    GPX4-IN-16
  • HY-149455

    Glutathione Peroxidase Cancer
    GPX4-IN-8 (compound A80) is a potent GPX4 inhibitor. GPX4-IN-8 shows antiproliferative activity .
    GPX4-IN-8
  • HY-149923

    Glutathione Peroxidase Cancer
    GPX4-IN-4 (Compound 24) is a potent GPX4 inhibitor. GPX4-IN-4 can be used for the research of cancer .
    GPX4-IN-4
  • HY-162717

    Glutathione Peroxidase Ferroptosis Cancer
    GPX4-IN-11 (compound I14) is a potent inhibitor of GPX4, with the KD of 45.7 μM. GPX4-IN-11 plays an important role in ferroptosis research .
    GPX4-IN-11
  • HY-162718

    Ferroptosis Cancer
    GPX4-IN-12 (compound I22) is a non-covalent GPX4 inhibitor. GPX4-IN-12 induces ferroptosis and inhibits cell growth of HT1080 cells .
    GPX4-IN-12
  • HY-162716

    Ferroptosis Cancer
    GPX4-IN-10 (compound I20) is a non-covalent GPX4 inhibitor. GPX4-IN-10 induces ferroptosis and inhibits cell growth of HT1080 cells .
    GPX4-IN-10
  • HY-157762

    Glutathione Peroxidase Ferroptosis Cancer
    GPX4-IN-9 (Compound A16) is a glutathione peroxidase 4 (GPX4) inhibitor that specifically targets GPX4 under both in vitro and in vivo conditions, inducing ferroptosis. GPX4-IN-9 exhibits cytotoxicity against pancreatic cancer cells and can be used in cancer research .
    GPX4-IN-9
  • HY-159990

    Glutathione Peroxidase Cancer
    GPX4-IN-15 (Compound C1) is an inhibitor for GPX4, that inhibits 19.8% GPX4 at 1 μM. GPX4-IN-15 inhibits the proliferation of cancer cell MDA-MB-468, BT-549 and MDA-MB-231 with IC50 of 0.86, 0.96 and 0.48 μM .
    GPX4-IN-15
  • HY-155664

    Glutathione Peroxidase Ferroptosis Cancer
    GPX4-IN-6 (Compound C25) is a GPX4 covalent inhibitor with an IC50 value of 0.13 μM. GPX4-IN-6 (Compound C25) can induce ferroptosis for the research of triple-negative breast cancer (TNBC) .
    GPX4-IN-6
  • HY-155663

    Glutathione Peroxidase Ferroptosis Cancer
    GPX4-IN-5 (Compound C18) is a GPX4 covalent inhibitor with an IC50 value of 0.12 μM. GPX4-IN-5 (Compound C18) can induce ferroptosis for the research of triple-negative breast cancer (TNBC) .
    GPX4-IN-5
  • HY-168011

    Ferroptosis Glutathione Peroxidase Reactive Oxygen Species Cancer
    GPX4-IN-14 (compound 2c) is an inhibitor of GPX4, with free radical scavenging activity (maximum scavenging rate is 72.52%) and anti-tumor proliferation activity in vitro. GPX4-IN-14 inhibits GPX4 protein, increases lipid peroxide levels and intracellular Reactive Oxygen Species (ROS) levels, thereby inducing ferroptosis and exerting anti-tumor proliferation effects .
    GPX4-IN-14
  • HY-115627
    PKUMDL-LC-101-D04
    2 Publications Verification

    GPX4-Activator-1d4

    Glutathione Peroxidase Inflammation/Immunology
    PKUMDL-LC-101-D04 (GPX4-Activator-1d4) is a glutathione peroxidase 4 (GPX4) allosteric activator (pEC50=4.7). PKUMDL-LC-101-D04 can inhibit ferroptosis and inflammation .
    PKUMDL-LC-101-D04
  • HY-161930

    PROTACs Ferroptosis Cancer
    PROTAC GPX4 degrader-3 is a potent PROTAC GPX4 degrader with a DC50 (24h) of 0.019 μM and an IC50 of 0.024 μM in HT1080 cell .
    PROTAC GPX4 degrader-3
  • HY-149236

    PROTACs Glutathione Peroxidase Ferroptosis Cancer
    PROTAC GPX4 degrader-1 (DC-2) is a PROTAC-based GPX4 degrader, with a DC50 of 0.03 μM in HT1080 cells .
    PROTAC GPX4 degrader-1
  • HY-162106

    Ferroptosis PROTACs Glutathione Peroxidase Cancer
    PROTAC GPX4 degrader-2 (compound 18a) is a proteolysis targeting chimeras (PROTACs) that can degrade glutathione peroxidase 4 (GPX4), with the DC50, 48h value of 1.68 μM. PROTAC GPX4 degrader-2 induces the accumulation of lipid peroxides and mitochondrial depolarization, subsequently triggering ferroptosis. PROTAC GPX4 degrader-2 has anti-proliferative effect .
    PROTAC GPX4 degrader-2
  • HY-100003
    ML-210
    10+ Cited Publications

    Glutathione Peroxidase Ferroptosis Cancer
    ML-210 is a selective and covalent glutathione peroxidase 4 (GPX4) inhibitor with an EC50 of 30 nM. ML-210 binds the GPX4 selenocysteine residue. ML-210 has anti-cancer activity .
    ML-210
  • HY-103087
    FIN56
    10+ Cited Publications

    Ferroptosis Others
    FIN56 is a specific inducer of ferroptosis. FIN56 induces ferroptosis by inducing degradation of GPX4. FIN56 also binds to and activates squalene synthase .
    FIN56
  • HY-100002
    ML162
    5+ Cited Publications

    Glutathione Peroxidase Ferroptosis Cancer
    ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor. ML162 has a selective lethal effect on mutant RAS oncogene-expressing cell lines
    ML162
  • HY-139001

    Glutathione Peroxidase Ferroptosis Others
    JKE-1716 is a potent and selective nitrolic acid-containing GPX4 inhibitor. JKE-1716 is able of inducing ferroptosis selectively through covalent GPX4 inhibition .
    JKE-1716
  • HY-129457
    FINO2
    5 Publications Verification

    Ferroptosis Cancer
    FINO2 is a potent ferroptosis inducer. FINO2 inhibits GPX4 activity. FINO2 is a stable oxidant that oxidizes ferrous iron and stable at varying pH levels. FINO2 causes widespread lipid peroxidation .
    FINO2
  • HY-157068

    Ferroptosis Glutathione Peroxidase Cancer
    icFSP1 is a potent ferroptosis suppressor protein-1 (FSP1) inhibitor. icFSP1 triggers subcellular relocalization of FSP1 from the membrane and FSP1 condensation, in synergism with GPX4 inhibition. icFSP1 induces ferroptosis. icFSP1 shows antitumor activity against melanoma. .
    icFSP1
  • HY-169133

    PROTACs Glutathione Peroxidase Ferroptosis Cancer
    GDCNF-11 is a HIM-PROTAC GPX4 degrader based on the chaperone protein HSP90. GDCNF-11 promotes the ubiquitination and degradation of GPX4 through the HSP 90 chaperone complex, reduces endogenous GPX4 expression to induce ferroptosis in HT-1080 cells, and the DC50 value is 0.08 μM (Pink: Target protein ligand (HY-153748); Blue: HSP90 ligand (HY-10212); Black: Linker (HY-W169526)) .
    GDCNF-11
  • HY-155852

    Ferroptosis Others
    Lepadin H is a marine alkaloid and ferroptosis inducer. Lepadin H exhibits significant cytotoxicity, promotes p53 expression, increases ROS production and lipid peroxidation, decreases SLC7A11 and GPX4 levels, and upregulates ACSL4 expression. Lepadin H induces ferroptosis through the p53-SLC7A11-GPX4 pathway .
    Lepadin H
  • HY-155952

    Glutathione Peroxidase Cancer
    LOC1886 is a covalent inhibitor of GPX4 with slightly lower potency than RSL3 and ML162 .
    LOC1886
  • HY-162065

    Ferroptosis Cancer
    N6F11 is a selective ferroptosis inducer, and can selectively induce ferroptosis by targeting TRIM25-mediated GPX4 degradation in cancer cells while sparing immune cells. N6F11 initiates HMGB1-dependent antitumor immunity mediated by CD8 + T cells [4].
    N6F11
  • HY-155851

    Ferroptosis MDM-2/p53 Glutathione Peroxidase Cancer
    Lepadin E is a significantly cytotoxic ferroptosis inducer that induces iron death through the classical p53-SLC7A11-GPX4 pathway. Lepadin E promoted p53 expression, decreases SLC7A11 and GPX4 levels, and leads to increased ROS and lipid peroxide production, and upregulated ACSL4 expression, thus causes cell death. Lepadin E has significant antitumor effect .
    Lepadin E
  • HY-N0070
    Solasonine
    2 Publications Verification

    Ferroptosis Glutathione Peroxidase Reactive Oxygen Species Cancer
    Solasonine is a ferroptosis inducer which can be isolated from Solanum melongena that has anti-infection, anti-cancer, and neurogenesis promoting properties. Solasonine promotes ferroptosis of HCC cells via destruction of the glutathione redox system induced by inhibiting GPX4, and can be used for cancer research .
    Solasonine
  • HY-100218A
    RSL3
    Maximum Cited Publications
    287 Publications Verification

    (1S,3R)-RSL3

    p62 Glutathione Peroxidase Ferroptosis Reactive Oxygen Species Cancer
    RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells .
    RSL3
  • HY-120912

    Keap1-Nrf2 Glutathione Peroxidase Ferroptosis Metabolic Disease Inflammation/Immunology Cancer
    Gingerenone A is an Nrf2-Gpx4 activator that can induce Ferroptosis in liver damage with oral activity. Gingerenone A has anti-inflammatory, anti-diabetic, anti-tumor, and pro-aging effects in mice [4].
    Gingerenone A
  • HY-N0070R

    Ferroptosis Glutathione Peroxidase Reactive Oxygen Species Cancer
    Solasonine (Standard) is the analytical standard of Solasonine. This product is intended for research and analytical applications. Solasonine is a ferroptosis inducer which can be isolated from Solanum melongena that has anti-infection, anti-cancer, and neurogenesis promoting properties. Solasonine promotes ferroptosis of HCC cells via destruction of the glutathione redox system induced by inhibiting GPX4, and can be used for cancer research .
    Solasonine (Standard)
  • HY-138153
    JKE-1674
    3 Publications Verification

    Glutathione Peroxidase Ferroptosis Cancer
    JKE-1674 is an orally active glutathione peroxidase 4 (GPX4) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into a nitrile oxide JKE-1777. JKE-1674 kills LOX-IMVI cells in a manner that is equipotent to ML-210 and is completely rescued by ferroptosis inhibitors .
    JKE-1674
  • HY-153748

    Glutathione Peroxidase Cancer
    ML162-yne is a potent GPX4-inhibitor affinity probe . ML162-yne is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    ML162-yne
  • HY-100218C

    Drug Isomer Ferroptosis Cancer
    (1R,3R)-RSL3 is an isomer of RSL3 (HY-100218A). RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells .
    (1R,3R)-RSL3
  • HY-161933

    PROTAC Linkers Cancer
    1-Adamantane-amide-C7-NH2 is the linker, which can be used for syntheisis of PROTAC GPX4 degrader-3 (HY-161930) .
    1-Adamantane-amide-C7-NH2
  • HY-167888

    Ferroptosis Glutathione Peroxidase Cancer
    NPD4928, a GPX4 inhibitor, enhances RSL3 (HY-100218A)-dependent ferroptosis. NPD4928 binds to ferroptosis suppressor protein 1 (FSP1) and inhibits its enzymatic activity .
    NPD4928
  • HY-151212

    Ferroptosis Glutathione Peroxidase Cancer
    BCP-T.A, a tunable heterocyclic electrophile, is a potent ferroptosis inducer by binding to GPX4 . BCP-T.A is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    BCP-T.A
  • HY-151429

    Apoptosis Ferroptosis Bcl-2 Family COX Cancer
    Antitumor agent-77 is an antitumor agent, inhibits cancer cells growth and migration. Antitumor agent-77 triggers ferroptosis by inhibiting GPx-4 and elevating COX2. Antitumor agent-77 also activates intrinsic apoptotic pathway (Bax-Bcl-2-caspase-3) and hinders Epithelial-mesenchymal transition (EMT) process of cancer cells .
    Antitumor agent-77
  • HY-151428

    Ferroptosis Apoptosis Bcl-2 Family COX Cancer
    Antitumor agent-78 is an antitumor agent, inhibits cancer cells growth and migration. Antitumor agent-78 triggers ferroptosis by inhibiting GPx-4 and elevating COX2. Antitumor agent-78 also activates intrinsic apoptotic pathway (Bax-Bcl-2-caspase-3) and hinders Epithelial-mesenchymal transition (EMT) process of cancer cells .
    Antitumor agent-78
  • HY-155075

    PROTACs Glutathione Peroxidase Ferroptosis Cancer
    NC-R17 is a PROTAC-class, non-covalent GPX4 degrader based on RSL3, involved in ferroptosis. NC-R17 has antitumor activity and is used for non-covalent GPX4 PROTAC design . NC-R17 consists of a target protein ligand (red part) Demethyl-RSL3 (HY-135832); an E3 ubiquitin ligase ligand (blue part) Lenalidomide (HY-A0003) and a PROTAC linker (black part) (HY-169376). E3 ubiquitin ligase and linker can form Lenalidomide-C13-piperazine-Boc (HY-169377) .
    NC-R17
  • HY-136057
    iFSP1
    15+ Cited Publications

    Ferroptosis Cancer
    iFSP1 is a potent, selective and glutathione-independent inhibitor of ferroptosis suppressor protein 1 (FSP1) (AIFM2) with an EC50 of 103 nM. iFSP1 selectively induces ferroptosis in GPX4-knockout cells which overexpressed FSP1. iFSP1 is able to sensitize a variety of human cancer cell lines to the ferroptosis inducer, such as (1S,3R)-RSL3 (HY-100218A) .
    iFSP1
  • HY-B0774
    Seratrodast
    4 Publications Verification

    AA 2414

    Ferroptosis JNK MDM-2/p53 Prostaglandin Receptor Reactive Oxygen Species Neurological Disease Inflammation/Immunology Endocrinology Cancer
    Seratrodast (AA 2414), an orally active antiasthmatic agent, is a thromboxane A2 receptor (TP) antagonist and ferroptosis inhibitor. Seratrodast reduces lipid ROS production, modulates the systemic xc-/GSH/GPX4 axis, and inhibits JNK phosphorylation and p53 expression. Seratrodast exhibits anti-asthmatic and anti-epileptic activity .
    Seratrodast
  • HY-157788

    PROTACs Reactive Oxygen Species Ferroptosis Glutathione Peroxidase Cancer
    ZX703 (compound 5I) is a PROTAC that significantly degrades GPX4 in a dose- and time-dependent manner through the ubiquitin-proteasome and autophagy-lysosome pathways (DC50=0.315 µM). ZX703 induces ferroptosis by inducing Reactive Oxygen Species (ROS) accumulation in cells. ZX703 can be used for cancer research .
    ZX703

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: